Login to Your Account



Agios Will Use $33M Series A to Target Cancer Metabolism

By Catherine Hollingsworth


Tuesday, July 8, 2008
Agios Pharmaceuticals said it plans to use the proceeds from a just-completed $33 million Series A financing to establish a product and biology platform focused on a new class of drugs that regulate cancer metabolism. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription